Medifast stock edges lower as guidance and analyst views diverge

Medifast, Inc. stock (ISIN US58470S1024) closed at USD 11.99 on the New York Stock Exchange on September 15, 2026, slightly below the average analyst price target of about USD 12.00 per share highlighted in recent data. On the same day, the shares showed a trailing year-to-date return of 12.27 percent versus 10.81 percent for the S&P 500, signaling modest outperformance despite operational headwinds.

Quarterly revenue drops but beats expectations

Known for its Optavia weight-loss and healthy-living program, Medifast reported revenue of USD 76.38 million for its latest quarter, down 27.6 percent year on year as the company navigates slower demand and competitive pressure in the personal care and nutrition space, according to StockStory in a sector review published on September 17, 2026. That decline still came in 5.1 percent above analyst expectations for the quarter’s revenue, pointing to a better-than-feared top-line performance for investors who had braced for deeper cuts.

The same overview notes that Medifast produced earnings per share guidance for the next quarter that exceeded analysts’ estimates and also beat consensus EPS for the reported period, according to StockStory. This mix of weaker revenue but stronger-than-expected profitability guidance makes Medifast one of the more surprising names in its personal care peer group, scoring the highest guidance raise while still posting the slowest revenue growth in that basket.

Analyst consensus sees sales under pressure

Analyst commentary reflects caution on Medifast’s sales trajectory even as some rating metrics remain supportive. Medifast currently carries a Zacks Rank #2 (Buy), indicating a generally favorable view on the shares, but the earnings history has been volatile, according to Zacks in an analyst blog dated September 17, 2026. Zacks highlights that Medifast has missed the average earnings surprise by a wide margin across the trailing four quarters, underscoring the risk that actual results could again deviate from forecasts.

For the current financial year, the Zacks Consensus Estimate points to a 27.3 percent decline in sales compared with the prior-year level, according to Zacks. That projected decline aligns closely with the latest quarterly year-on-year revenue drop of 27.6 percent and suggests that analysts do not yet expect a rapid recovery in demand for Medifast’s products over the remainder of the year.

Price-target data on Medifast also show a relatively tight range around the current share price level. Recent figures indicate an average analyst price target near USD 12.00 per share, a high target around USD 12.00 and a current price of USD 11.99, implying limited upside embedded in near-term expectations based on the latest data snapshot from a major financial portal. This narrow gap between the market price and targets underlines that, for now, investors appear to be pricing in much of the expected earnings and revenue trajectory.

Stock performance and valuation context

At a closing price of USD 11.99 on September 15, 2026, Medifast stock trades only marginally below the latest average analyst target, yet it has delivered a 12.27 percent year-to-date total return compared with 10.81 percent for the S&P 500 benchmark over the same period, based on trailing total returns figures reported in recent market data. The one-year total return stands at 15.68 percent versus 14.67 percent for the S&P 500, illustrating that, despite fundamental challenges, Medifast has modestly outpaced the broader market over the last twelve months.

Sector comparisons from the personal care space show Medifast’s share price reacting positively to its recent quarterly report, with the stock up 22.8 percent since the earnings release and currently trading at about USD 11.96 in that snapshot, according to StockStory. For investors, that combination of a more than 20 percent post-earnings gain and only a small gap to prevailing price targets suggests the market has already rewarded the guidance surprise, potentially limiting further near-term rerating unless revenue trends stabilize.

While specific market-capitalization and 52-week range figures are not detailed in the latest week-filtered sources, the stock’s performance relative to the index and peers offers a helpful lens on valuation. A mid-teens one-year return coupled with a forecast near-30 percent sales decline implies that much of the share-price resilience stems from expectations of cost discipline and margin management rather than robust top-line growth, an important nuance for investors weighing Medifast against other personal care and consumer health names.

Risks around execution and demand

The key risk highlighted in recent analyst commentary is execution against guidance in an environment of weakening revenue. The fact that Medifast has missed the average earnings surprise significantly over the past four quarters, as noted by Zacks, underscores the risk that future results could again fall short of optimistic guidance if consumer demand or coach network dynamics prove less supportive than anticipated.

Another structural risk arises from the competitive landscape in weight management and healthy living products. Medifast’s Optavia program competes not only with traditional diet plans and meal-replacement offerings but increasingly with digital health apps, prescription-based weight-loss treatments and broader wellness platforms, according to the sector framing in StockStory. In such a context, sustaining revenue growth after a 27.6 percent year-on-year drop will likely depend on Medifast’s ability to differentiate its offerings and retain its coach and customer base.

For investors, this means the current thesis hinges on management delivering on EPS guidance and stabilizing revenue, rather than on aggressive top-line expansion. The modest premium of Medifast’s one-year total return over the S&P 500, together with a share price that sits close to average analyst targets, paints a picture of a stock where expectations are balanced between cautious fundamental outlook and confidence in cost and margin controls.

Medifast stock holds near recent levels

Medifast stock most recently closed at USD 11.99 on the New York Stock Exchange on September 15, 2026, with that price serving as a reference point for current valuation discussions. With the shares trading effectively in line with recent analyst price targets around USD 12.00, the market appears to be waiting for clearer evidence from upcoming results on whether the company can offset forecast sales declines through execution on guidance and margin management.

More news and analyses on Medifast, Inc. stock